Direct renin inhibition: An evaluation of the safety and tolerability of aliskiren

Current Medical Research and Opinion

Volumn 24, Issue 9, 2008, Pages 2627-2637

  Rashid, Haroonur ^a,b  

^a ST LUKE S EPISCOPAL HOSPITAL   (United States)

^b Kelsey Seybold Clinic   (United States)

Author keywords

Aliskiren; Drug interaction; Hypertension; Renin inhibition; Renin angiotensin aldosterone system; Safety

Indexed keywords

ALISKIREN; ALLOPURINOL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; CAPTOPRIL; CELECOXIB; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FENOFIBRATE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; LOSARTAN; METFORMIN; MEVINOLIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; RENIN; RENIN INHIBITOR; VALSARTAN; WARFARIN;

ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; AREA UNDER THE CURVE; BACKACHE; BRONCHITIS; CHRONIC PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIARRHEA; DIZZINESS; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG FATALITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ENZYME INHIBITION; FATIGUE; GERIATRIC PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPOTENSION; INFLUENZA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; LIVER DISEASE; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MONOTHERAPY; PATIENT SAFETY; PERIPHERAL EDEMA; POTASSIUM EXCRETION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; UREA NITROGEN BLOOD LEVEL;

AMIDES; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; FUMARATES; HUMANS; PLACEBOS; RENIN;

EID: 53349092083     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802336541     Document Type: Review

References (43)

1. Atlas SA. The renin-angiotensin-aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm 2007-13(Suppl B)9-20
2. Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005; 111: 1012-18
3. Oh B-H, Mitchell J, Herron JR, et al. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007;49:1157-63
4. Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 20031;42:1137-43
5. Strasser RH, Puig JG, Farsang C, et al. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007; 21:780-7
6. Uresin Y, Taylor AA, Kilo C, et al. Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension. J Renin Angiotensin Aldosterone Syst 2007;8:190-8
7. Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007; 20:11-20
8. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370:221-9
9. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25:217-26
10. Jordan J, Engeli S, Boye SW, et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension 20071;49:1047-55
11. Drummond W, Munger MA, Rafique EM, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007;9:742-50
12. Tekturna® (aliskiren) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; March 2007.
13. Vaidyanathan S, Reynolds C, Yeh C-M, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007; 47:453-60
14. Shafiq MM, Menon DV, Victor RG. Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug, Am J Med 2008;121:265-71
15. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004; 351:585-92
16. Parfrey PS. Inhibitors of the renin-angiotensin system: proven benefits, unproven safety. Ann Intern Med. 2008;148:74-77
17. The PEACE Trial InvestigatorsAngiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351:2058-68
18. Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51
19. Karlberg BE. Cough and inhibition of the renin-angiotensin system. J Hypertens Suppl 1993;11:49-52
20. Weir MR, Bush C, Anderson DR, et al. Antihypertensive efficacy, safety and tolerability of the oral renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens 2007;1:264-77
21. US Food and Drug Administration. Title 21 - food and drugs chapter 1 - Food and Drug Administration Department of Health and Human Services Subchapter D - drugs for human use. Available from https://www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm [Accessed 3/7/2008].
22. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation. In Press.
23. Gradman AH, Kolloch RE, Meyers M, et al. Aliskiren in combination with hydrochlorothiazide is effective and well tolerated during long-term treatment of hypertension [abstract]. J Clin Hypertens 2007;9(Suppl A5)A160
24. Tekturna HCT [prescribing information]. East Hanover, NJ: Novartis Pharmaceutical Corporation; January 2008.
25. Vaidyanathan S, Valencia J, Kemp C, et al. Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers. Int J Clin Pract 2006;60:1343-56
26. Zhao C, Vaidyanathan S, Dieterich HA, et al. Assessment of the pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and furosemide: a study in healthy volunteers [abstract]. Clin Pharmacol Ther 2007;81 (Suppl 1)S110
27. Dieterich HA, Warren V, Sabo R, et al. Lack of pharmacokinetic interaction between the oral direct renin inhibitor aliskiren and pioglitazone or fenofibrate in healthy volunteers [abstract]. Basic Clin Pharmacol Toxicol 2007;101:135-6
28. Reynolds C, Vaidyanathan S, Dieterich HA, et al. Assessment of pharmacokinetic interaction between aliskiren, a novel direct renin inhibitor, and metformin in healthy volunteers [abstract]. Clin Pharmacol Ther 2006;81 (Suppl 1)S110
29. Ayalasomayajula S, Tchaloyan S, Yeh CM, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with allopurinol, celecoxib and cimetidine in healthy subjects. Curr Med Res Opin 2008;24:717-26
30. Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atovastatin and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol. In Press.
31. Dieterle W, Corynen S, Mann J. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 2004;58:433-6
32. Dieterle W, Corynen S, Vaidyanathan S, et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pbarmacol Ther 2005;43:527-35
33. Vaidyanathan S, Bigler H, Yeh C, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007;146:661-75
34. Bindschedler M, Degen P, Flesch G, et al. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide. Eur J Clin Pharmacol 1997;52:371-8
35. Viazzi F, Leoncini G, Ratto E, et al. Mild hyperuricemia and subclinical renal damage in untreated primary hypertension. Am J Hypertens 2007;20:1276-82
36. Vaidyanathan S, Jin Y, Schiller H, et al. Aliskiren, a novel oral renin inhibitor, has no interaction with cytochrome P450 isoenzymes in vitro. Basic Clin Pharmacol Toxicol. In Press.
37. Azizi M, Webb R, Nussberger J, et al. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens. 2006;24:243-56
38. Barnett AH, Bain SC, Bouter P, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61
39. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008;358:2433-46
40. Zhao C, Vaidyanathan S, Yeh C-M, et al. Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 2006; 45:1125-34
41. Verdecchia P, Calve, C, Mockel V, et al. Safety and efficacy of the oral direct renin inhibitor aliskiren in elderly patients with hypertension. Blood Press 2007;16:381-91
42. Fisher ND, Hollenherg NK. Unprecedented renal responses to direct blockade of the renin-angiotensin-system with aliskiren, a novel renin inhibitor. Presented at: American Heart Association Scientific Sessions; November 3-7, 2007; Orlando, FL.
43. Vaidyanathan S, Warren V, Yeh C, et al. Pharmacokinetics, safety, and tolerability of the oral renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47:192-200